evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 4 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 1 · 16.7%Very low 2 · 33.3%Low 3 · 50%Moderate 0 · 0%High 0 · 0%

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality at day 28 · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The intervention may leads to lower all‐cause mortality at day 28 (low certainty).

1 finding from 1 review

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE

It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).

1 finding from 1 review

Perioperative beta‐blockers vs placebo or usual care

Early all‐cause mortality (within 30 days) · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)

Perioperative beta‐blockers showed no clear difference in early all‐cause mortality (within 30 days) compared with placebo or standard care (low certainty).

1 finding from 1 review